In the year before COVID-19 struck, the molecular diagnostics and life sciences company Qiagen NV initiated several changes that not only helped it set a new strategic direction, but also as it transpired, manage a sound course through the pandemic that took hold in early 2020.
Company CFO and managing director Roland Sackers referred to those changes implemented by the Netherlands-based, New York-listed holding company as he delivered a corporate performance commentary and outlook at the...